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Preterm infants are susceptible to opportunistic infection because of their immature 
immune system.  As to fungal infection, Aspergillosis is second only to Candida infection in 
these patients.   
Here we report the case of an extremely low birth weight (ELBW) infant who developed 
pulmonary Aspergillosis and was successfully treated by micafungin (echinocandins).  The 
infection occurred in the cavity in chronic lung disease and was diagnosed by typical CT 
imaging and detection of Aspergillus galactmannan antigen in the serum specimen.  To our 
knowledge, this is the first report of pulmonary Aspergillosis treated with micafungin in 
ELBW infants. 
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Improvement of perinatal and neonatal care has resulted in the increased survival of 
extremely low birth weight (ELBW) infants, but invasive fungal infection is one of the 
leading causes of morbidity.  In addition to their immature immune system, the presence of a 
central catheter, endotracheal tubes, and many drugs, including broad-spectrum antibiotics 
and glucocorticoids, aggravates their susceptibility to fungal infections.  Invasive 
Candidiasis is a leading cause of infection-related mortality in ELBW infants, and neonatal 
cases of pulmonary candidiasis have already been reported or reviewed[1].  By comparison, 
there are very few reports about Aspergillosis except for sporadic cases of invasive pulmonary 
Aspergillosis (IPA), especially Aspergilloma.  As the invasive Aspergillosis is a major threat 
for preterm infants due to high morbidity and mortality rates [2,3,4], the most important issue 
is an early diagnosis before dissemination and an appropriate choice of antifungal agents.  
 Here, we report the case of a neonate with pulmonary Aspergillosis.  The diagnosis 
was made by typical CT imaging and abnormal elevation of serum galactomannan antigen. 






A male pre-term infant was admitted to our NICU after delivery at 25 weeks and 3 
days of gestation (birth weight 808g) by emergent cesarean section because of uncontrollable 
uterine contractions associated with chorioamnionitis.  Apgar scores were 1 and 4 at 1 and 5 
minutes, respectively.  He was immediately intubated and artificially ventilation was started.  
Although he had no sign of RDS, he had significant persistent ductus arteriosus and was 
treated with indomethacin and surgical ligation.  From 3 days of age, his serial chest 
radiographs gradually showed a reticulogranular pattern (Figure 1), so we started inhaled 
steroid therapy using 50μg fluticasone propionate twice daily from 4 days of age.  Then, at 
17 days of life, the infant developed oligourea and hypotension with hyponatremia, and 
late-onset circulatory dysfunction was suspected.  We stopped inhaled steroid therapy and 
started systemic steroid administration.  Total doses of systemic steroid, from 17 to 63 days 
of age, were 48.5mg of hydrocortisone and 3.55mg of dexamethasone.  During steroid 
therapy, he suffered from methicillin-resistant Staphylococcus aureus (MRSA) pneumonia 
from 27 days of age and CRP elevated to 8.0mg/dl.  He recovered after treatment with 
antibiotics (teicoplanin) and gammaglobulin but multiple bulla formation in the bilateral lung 
field emerged.  
He was extubated from mechanical ventilation at 38 days of life and was then put on nasal 
CPAP (continuous positive airway pressure).  He discontinued nasal CPAP at 64 days of age, 
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but required low-flow oxygen via a nasal cannula. He was reintubated twice for a short period, 
at 60 and 76 days of life, because he needed laser photocoagulation therapy for retinopathy of 
prematurity. 
From about 60 days of life, his laboratory investigation showed low positive C-reactive 
protein and leukocytosis, and chest radiograph revealed a solid round infiltration in the middle 
lobe of the right lung.  We started antibiotic therapy with teicoplanin and ceftazidime from 
76 days of age, but CRP did not normalize.  Laboratory findings at 82 days of age showed 
weakly positive β-D-glucan at 6.608 pg/ml (the kinetic turbidimetric Limulus method 
[Beta-Glucan test; Wako]; normal range <3.95pg/ml) with WBC 14,200/μl and CRP 0.7mg/dl.  
High-resolution CT of the lung revealed a ball-like cavity in the right middle lobe with fluid 
collection, called “air space consolidation” (Figure 2), which was identified by transthorathic 
echography (transducer is placed in the fourth or fifth left intercostal space on the midaxillary 
line).  
We used fluconazole as the first-line drug for 2 days, and then replaced it with micafungin 
because ELISA for galactomannan aspergillus antigen proved to be positive (the index was 
2.3; normal range is <0.5).  Initially we started at a dose of 2 mg/kg/day over 1 hour for 2 
days, and then, increased up to 5mg/kg/day and maintained for 21 days from 89 to 109 days 
of age.  After the initiation of micafangin, he showed neither symptoms related to fungal 
infection nor adverse events associated with the treatment.  The lesion had almost 
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disappeared on chest CT imaging at 131 days of age and serum galactomannan antigen 
became negative at 141 days of age, lower than 0.5 (the index was 0.3).  
He was discharged from our NICU at 150 days of age without any complications.  Now he is 
3 years old and has not experienced any signs of recurrence of Aspergillus infection. 
We measured the serum concentration of micafungin twice.  The first time, from 97 to 98 
days of age, peak and trough concentrations were 8.6 and 6.39μg/ml, respectively.  From 108 
to 109 days of age, these were 3.98 and 1.29μg/ml, respectively. Although the concentrations 
of the medicine were lower than expected, his clinical course was acceptable and we did not 
increase the dosage.   
We found no immune dysfunction, including the superoxide production ability and phagocytic 




Discussion   
Nosocomial Aspergillus infection represents a serious threat for severely 
immunocompromised patients [5].  Prematurity is a risk factor for invasive Aspergillosis, 
and a birth weight of <1500g is also considered as a risk factor [6].  Preterm neonates have 
several risk factors, including cavitary lung disease, steroid use or immaturity of the immune 
system[7].  In adult patients, the infection mostly strikes the lung.  Invasion by the fungus 
usually follows its inhalation and colonization of airways, and cutaneous Aspergillosis is 
reported as a late manifestation of haematogenous dissemination. In contrast to the adults, 
because of the immature skin, superficial skin infections are considered important as the first 
colonization of Aspergillus in preterm neonates [8].  
Our patient had all of these risk factors, developed pulmonary Aspergillosis and is 
considered a typical case; however, no cutaneous lesion was found and skin colonization was 
not detected throughout his clinical courses.  We suspect that inhaled pores accumulated in 
small cavities associated with BPD, where macrophages could not reached.   Our case 
suggested that cutaneous lesions did not always precede invasive Aspergillus infection and 
that negative skin surveillance results did not reduce its possibility.  
Diagnosis is divided into three categories; proven, probable, and suspected invasive 
fungal infection[9].  Proven infection requires detection of the fungus itself, but definitive 
diagnosis by tissue microscopy and culture is difficult in the early stage of infection, and is 
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too invasive for neonates.  Aspergilloma was therefore diagnosed from his clinical course, 
typical pulmonary CT imaging and serum galactomannan antigen.  Even mild increase of 
galactomannan antigen could be diagnostic for Aspergillosis [10,11], and the importance of a 
regular survey of galactomannan antigen was reported by Sulahian [12].  In our case, CRP 
and β-D-glucan was slightly increased, and the X-ray showed a cavity in the lung regardless 
an antibiotic therapy, so we suspected Aspergillus pneumonia and diagnosed “probable 
Aspergilloma” due to positive galactomannan antigen (2.3).   
Antifungal therapy has changed by the innovation of new anti-fungal agents during 
the past decade.  New agents are expected to have a broader spectrum with fewer side effects, 
and their efficacy and safety have been intensely investigated in adults but an information for 
children is still limited [8,13,14,15].  Antifungal agents commonly used are classified into 
four categories: polyene macrolides, fluorinated pyrimidines, triazoles, and echinocandins[16].  
Prasad et al. surveyed the trend for anti-fungal therapy in pediatric patients from 2000 to 2006 
[17].  Based on their report, the most commonly prescribed antifungal agent was fluconazole 
(76%), followed by amphotericin preparations (26%).  Prescriptions for voriconazole and 
echinocandin are steadily increasing and replacing amphotericin B (AMB) for the treatment 
of Aspergillosis [18,19].  But the increase in echinocandin use was almost entirely 
attributable to the use of caspofungin [20], and reports of infants treated with micafungin are 
exclusively limited.  Micafungin is a new echinocandin that works by inhibiting 
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1,3-β-D-glucan synthesis, an enzyme responsible for fungal cell wall synthesis, and it is 
licensed in Japan as the only medicine for pediatric invasive fungal infections.  Micafungin 
has a broad spectrum for candida and Aspergillus species.  There are reports on the 
pharmacokinetics data for micafungin in preterm infants[21,22,23,24,25], which exhibited a 
linear plasma pattern in the range 0.25-16mg/kg[26].  In our case, administration of 
5mg/kg/day micafungin for three weeks resulted in a relatively low plasma concentration 
compared to the report for adults, however, the anti-fungal effects were sufficient, and no side 
effects were observed.   
Our limited experience suggested that micafungin could be a good choice for the treatment of 
infants with invasive Aspergillosis.   
 
Conclusion 
We experienced an extremely preterm male infant infected with probable pulmonary 
Aspergillosis.  The detection of Aspergillus was difficult but serum galactomannan antigen 
was useful for the diagnosis. Administration of 5mg/kg/day micafungin for three weeks 
resulted in clinical improvement without complications, and we consider that micafungin 
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Fig. 1. Chest radiography of the infant showing reticulogranular pattern of the whole lobes. 
Fig. 2. Computed tomography of the right middle lobe showing a ball-like cavity with fluid 
collection 
 


